Regeneron Pharmaceuticals Inc

REGNNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
664.52 USD
↘ 3.43 (0.51%)AT CLOSE (11:59 AM EDT)
664.00
↘ 0.52 (0.08%)
POST MARKET (AS OF 07:21 PM EDT)
Post Market
AS OF 07:21 PM EDT
664.00
↘ 0.52 (0.08%)
🔴Market: CLOSED

Regeneron Pharmaceuticals Inc (REGN) trades at $664.52 per share. The technical outlook is "Buy" and the fundamental picture shows "Neutral". Key drivers include a robust Altman Z-Score and a bearish Death Cross on the long-term moving averages. On the valuation side, REGN appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Jul 10, 2026.

Open?$670.06
High?$676.66
Low?$658.50
Prev. Close?$667.95
Volume?581.8K
Avg. Volume?1.1M
VWAP?$662.49
Rel. Volume?0.54x
Bid / Ask
Bid?$661.90 × 80
Ask?$676.30 × 40
Spread?$14.40
Midpoint?$669.10
Valuation & Ratios
Market Cap?69.7B
Shares Out?103.0M
Float?98.3M
Float %?94.6%
P/E Ratio?15.75
P/B Ratio?2.22
EPS?$42.19
Dividend?0.54%
Ex-Dividend?N/A
News
Profile
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Themes
Biotech - Drug Development›Immunology & AutoimmuneHealthcare - Oncology›Immunotherapy & Immuno-OncologyHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
15.4K
Market Cap
69.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.regeneron.com
Listed
1991-04-02
Address
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
Phone: (914) 847-7000
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
100
Momentum?
45
Short Sent.?
50
Piotroski F-Score?4/9Mixed
Altman Z-Score?6.72Safe
Confidence?66%Moderate
Full Fundamental Analysis →
Short InterestLow
Short % of Float?3.55%Low
Short Interest?3.5M
Days to Cover?2.9
Free Float98.3M
Avg Daily Volume1.2M
Settlement Date2026-06-30
Financial Health
Current Ratio?3.57Strong
Quick Ratio?2.96Strong
Cash Ratio?0.58Adequate
Debt/Equity?0.09Low
ValuationATTRACTIVELY VALUEDvs 10 peers + S&P 500
Score
83/100
P/E?
Peers
100
S&P
78
15.8CHEAP▾
P/B?
Peers
80
S&P
69
2.22CHEAP▾
P/S?
Peers
82
S&P
32
4.67FAIR▾
P/FCF?
Peers
75
S&P
67
16.9CHEAP▾
EV/EBITDA?
Peers
63
S&P
39
16.7FAIR▾
EV/Sales?
Peers
91
S&P
39
4.65FAIR▾
Returns & Efficiency
ROE?
Peers
29
S&P
51
14.1%STRONG▾
ROA?
Peers
63
S&P
77
10.8%STRONG▾
Cash Flow & Enterprise
FCF?$4.1B
Enterprise Value?$69.4B
Fundamentals ratios updated end of day
MarketsMoversWatchlist